Literature DB >> 12518351

Interferon alfa-2a in recurrent metastatic hemangiopericytoma.

Herwig Lackner1, Christian Urban, Hans Jürgen Dornbusch, Wolfgang Schwinger, Reinhold Kerbl, Petra Sovinz.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12518351     DOI: 10.1002/mpo.10122

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


× No keyword cloud information.
  6 in total

Review 1.  Primary haemangiopericytoma of the parapharyngeal space: an unusual tumour and review of the literature.

Authors:  E N Fountoulakis; E Papadaki; I Panagiotaki; E Giannikaki; G Lagoudianakis; J Bizakis
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-03-16       Impact factor: 2.124

2.  Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma.

Authors:  Su Jin Lee; Seung Tae Kim; Se Hoon Park; Yoon La Choi; Jae Berm Park; Sung-Joo Kim; Jeeyun Lee
Journal:  Clin Sarcoma Res       Date:  2014-09-24

3.  Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver.

Authors:  Sara Velayati; Joseph P Erinjeri; Lynn A Brody; Etay Ziv; Franz E Boas; Karen T Brown; Anne M Covey; George I Getrajdman; Stephen B Solomon; Peter T Kingham; William D Tap; William R Jarnagin; Hooman Yarmohammadi
Journal:  Sarcoma       Date:  2019-09-03

Review 4.  Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.

Authors:  Jin Yuan; Xiaoyang Li; Shengji Yu
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

5.  Retroperitoneal solitary fibrous tumor: surgery as first line therapy.

Authors:  Rahul Rajeev; Mohit Patel; Thejus T Jayakrishnan; Fabian M Johnston; Meena Bedi; John Charlson; Kiran K Turaga
Journal:  Clin Sarcoma Res       Date:  2015-08-27

6.  Sacro-anterior haemangiopericytoma: a case report.

Authors:  Xiu-Hong Ge; Shuai-Shuai Liu; Hu-Sheng Shan; Zhi-Min Wang; Qian-Wen Li
Journal:  Cancer Biol Med       Date:  2014-06       Impact factor: 4.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.